{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "https://eldaddp.azurewebsites.net/answeredquestions.text?min-questionFirstAnswered.=2024-04-09T11%3A12%3A25.547Z&answeringDeptId=17&max-dateTabled=2024-03-27", "definition" : "https://eldaddp.azurewebsites.net/meta/answeredquestions.text?min-questionFirstAnswered.=2024-04-09T11%3A12%3A25.547Z&answeringDeptId=17&max-dateTabled=2024-03-27", "extendedMetadataVersion" : "https://eldaddp.azurewebsites.net/answeredquestions.text?min-questionFirstAnswered.=2024-04-09T11%3A12%3A25.547Z&answeringDeptId=17&max-dateTabled=2024-03-27&_metadata=all", "first" : "https://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&min-questionFirstAnswered.=2024-04-09T11%3A12%3A25.547Z&answeringDeptId=17&max-dateTabled=2024-03-27", "hasPart" : "https://eldaddp.azurewebsites.net/answeredquestions.text?min-questionFirstAnswered.=2024-04-09T11%3A12%3A25.547Z&answeringDeptId=17&max-dateTabled=2024-03-27", "isPartOf" : "https://eldaddp.azurewebsites.net/answeredquestions.text?min-questionFirstAnswered.=2024-04-09T11%3A12%3A25.547Z&answeringDeptId=17&max-dateTabled=2024-03-27", "items" : [{"_about" : "http://data.parliament.uk/resources/1699316", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1699316/answer", "answerText" : {"_value" : "

At the time of answering, the Department was engaged in commercial negotiations with NHS Supply Chain and their sub-contractors, relating to ongoing storage requirements for the COVID Strategic Intensive Care Unit. In December 2023, the average per pallet per week cost for equipment in the COVID Strategic Intensive Care Unit was £5.52.<\/p>

The Department currently makes payments to NHS Supply Chain in relation to storage of personal protective equipment (PPE). At end of December 2023 there were 492,259 pallets, or 5.1 billion items, of COVID-19 PPE remining in storage. This includes both business as usual and excess stock.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4948", "label" : {"_value" : "Biography information for Lord Markham"} } , "answeringMemberPrinted" : {"_value" : "Lord Markham"} , "dateOfAnswer" : {"_value" : "2024-04-09", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-04-09T13:31:41.717Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-03-27", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Medical Equipment: Storage"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask His Majesty's Government, further to the Written Answer by Lord Markham on 9 February (HL2216), why the information mentioned in the Answer on government expenditure is commercially sensitive.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4347", "label" : {"_value" : "Biography information for Baroness Wolf of Dulwich"} } , "tablingMemberPrinted" : [{"_value" : "Baroness Wolf of Dulwich"} ], "uin" : "HL3713"} , {"_about" : "http://data.parliament.uk/resources/1699327", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1699327/answer", "answerText" : {"_value" : "

No such assessment has been made.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4948", "label" : {"_value" : "Biography information for Lord Markham"} } , "answeringMemberPrinted" : {"_value" : "Lord Markham"} , "dateOfAnswer" : {"_value" : "2024-04-10", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-04-10T12:43:43.227Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-03-27", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Population"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask His Majesty's Government what assessment they have made of the impact on the UK of the global decline in fertility rates.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4321", "label" : {"_value" : "Biography information for Lord Farmer"} } , "tablingMemberPrinted" : [{"_value" : "Lord Farmer"} ], "uin" : "HL3671"} , {"_about" : "http://data.parliament.uk/resources/1699328", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1699328/answer", "answerText" : {"_value" : "

No assessment has been made of the impact of the Abortion Act 1967 on United Kingdom birth rates. Parliament decided the circumstances under which abortion can legally be undertaken. Under the act, women have access to safe, legal, regulated abortion services.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4948", "label" : {"_value" : "Biography information for Lord Markham"} } , "answeringMemberPrinted" : {"_value" : "Lord Markham"} , "dateOfAnswer" : {"_value" : "2024-04-10", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-04-10T11:07:17.327Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-03-27", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Birth Rate"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask His Majesty's Government what assessment they have made of the impact of the Abortion Act 1967 on UK birth rates.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4321", "label" : {"_value" : "Biography information for Lord Farmer"} } , "tablingMemberPrinted" : [{"_value" : "Lord Farmer"} ], "uin" : "HL3672"} , {"_about" : "http://data.parliament.uk/resources/1699329", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1699329/answer", "answerText" : {"_value" : "

We want to ensure that all children and young people get the mental health support they need, including boys.<\/p>

By the end of 2023/24 the overall spending on mental health has increased by more than £4.7 billion in cash terms since 2018/19 (before the COVID-19 lockdown restrictions were introduced).<\/p>

There are now around 400 mental health support teams in place across England, covering 3.4 million children or around 35% of pupils in schools and colleges. We estimate this will increase to 44% by April 2024 and we are working to increase this coverage to 50% of pupils by March 2025.<\/p>

There are also currently around 65 locally funded early support hubs in England. These hubs are open to those aged 11 to 25 years old and, importantly, they are for anyone who may not meet the threshold to receive National Health Service support. Following a competitive commercial process from hubs across the country, the government is now providing up to £8 million to 24 existing hubs to provide even more support. This means children and young people, including boys, who are experiencing feelings of anxiety or stress will have a physical space to go to in their community when their problems first emerge, without the need for a referral.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4948", "label" : {"_value" : "Biography information for Lord Markham"} } , "answeringMemberPrinted" : {"_value" : "Lord Markham"} , "dateOfAnswer" : {"_value" : "2024-04-10", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-04-10T11:07:05.607Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-03-27", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Mental Health: Boys"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask His Majesty's Government what action they are taking to help the mental health of boys who were impacted by the lockdown restrictions.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4321", "label" : {"_value" : "Biography information for Lord Farmer"} } , "tablingMemberPrinted" : [{"_value" : "Lord Farmer"} ], "uin" : "HL3673"} , {"_about" : "http://data.parliament.uk/resources/1698892", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1698892/answer", "answerText" : {"_value" : "

The Department has been working closely with the General Medical Council (GMC) since 2019, on the regulation of Anaesthesia Associates (AAs) and Physician Associates (PAs). Regulation with the GMC will provide set standards of practice, education, and training for AAs and PAs, as well as requirements around continual professional development (CPD) and conduct. Regulation with the GMC will mean that individual AAs and PAs can be held to account if serious concerns are raised.<\/p>

<\/p>

The NHS Long Term Workforce Plan commits to growing these roles alongside recruiting and training more doctors, nurses, and allied health and other professionals. NHS England is working with partners, including the GMC, royal colleges, trade unions, doctors, and medical associate professional groups to develop comprehensive curricula, core capability frameworks, standards for CPD, assessment and appraisal, and supervision guidance for AAs and PAs, ensuring the roles are expanded safely and effectively.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"} } , "answeringMemberConstituency" : {"_value" : "Pendle"} , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"} , "dateOfAnswer" : {"_value" : "2024-04-15", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-04-15T08:29:10.19Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-03-26", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Anaesthesia Associates and Physician Associates"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what recent discussions she has had with the General Medical Council on (a) regulating (i) physician and (ii) anaesthesia associates and (b) ensuring that increased use of these roles in hospitals does not impact (A) the professional competence of other healthcare professionals and (B) patient safety.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4471", "label" : {"_value" : "Biography information for Rachael Maskell"} } , "tablingMemberConstituency" : {"_value" : "York Central"} , "tablingMemberPrinted" : [{"_value" : "Rachael Maskell"} ], "uin" : "20681"} , {"_about" : "http://data.parliament.uk/resources/1698899", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1698899/answer", "answerText" : {"_value" : "

It is the responsibility of professionals and their employers to ensure professional titles are used appropriately, and are not misleading to patients. National Institute for Health and Care Excellence (NICE) guidelines set out that all healthcare professionals directly involved in a patient's care should introduce themselves and explain to the patient: who is responsible for their clinical care and treatment; the roles and responsibilities of the different members of the healthcare team; and the communication about their care that takes place between members of the healthcare team.<\/p>

<\/p>

Professions that are regulated in statute have titles that are protected by law, and professionals must be registered with a statutory regulator to use them. It is an offence for a person to use a title they are not legally permitted to use, or to otherwise hold themselves out to be a regulated professional.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"} } , "answeringMemberConstituency" : {"_value" : "Pendle"} , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"} , "dateOfAnswer" : {"_value" : "2024-04-15", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-04-15T08:28:46.783Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-03-26", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Health Professions"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what discussions she is having with professional bodies on ensuring that the public have a clear understanding of (a) professional titles and (b) the services they can expect from the holders of such titles.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4471", "label" : {"_value" : "Biography information for Rachael Maskell"} } , "tablingMemberConstituency" : {"_value" : "York Central"} , "tablingMemberPrinted" : [{"_value" : "Rachael Maskell"} ], "uin" : "20682"} , {"_about" : "http://data.parliament.uk/resources/1698907", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1698907/answer", "answerText" : {"_value" : "

Preliminary findings for the Department's workforce reform programme have indicated that workers with multiple positive employment factors, including increasing access to training and qualifications, were more likely to stay in employment. Planned evaluation of the reforms will aim to measure the impact on intention to leave, and actual turnover, along with other outcomes.<\/p>

We anticipate benefits from the workforce reform programme will include a reduction in staff turnover, improved quality of care from a better trained and more stable workforce, increased workforce productivity, and an increase in efficiency savings for social care providers as they reduce the amount of retraining and recruitment needed. These all contribute to our wider goals of improvements in the quality-of-care provision and improved access to care.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4527", "label" : {"_value" : "Biography information for Helen Whately"} } , "answeringMemberConstituency" : {"_value" : "Faversham and Mid Kent"} , "answeringMemberPrinted" : {"_value" : "Helen Whately"} , "dateOfAnswer" : {"_value" : "2024-04-15", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-04-15T08:28:23.613Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-03-26", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Social Services"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether she has made an assessment of the potential impact of her policies on social care on (a) staff recruitment and retention and (b) service user outcomes.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4471", "label" : {"_value" : "Biography information for Rachael Maskell"} } , "tablingMemberConstituency" : {"_value" : "York Central"} , "tablingMemberPrinted" : [{"_value" : "Rachael Maskell"} ], "uin" : "20683"} , {"_about" : "http://data.parliament.uk/resources/1698922", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1698922/answer", "answerText" : {"_value" : "

The Government is undertaking a number of actions to address the risk that synthetic opioids pose. The Department has a longstanding surveillance system in place to collect information on the nature and location of novel drug use, drug markets, and reports alerting us to drug harms experienced. We continue to monitor the threat posed by synthetic opioids, and are working to improve drug surveillance on synthetic opioids through the development of an early warning system. This will include, with the permission of coroners, toxicology results for fatal overdose cases from across England as soon as the information is available, enabling the Department to closely monitor the substances causing deaths.<\/p>

<\/p>

We know that most overdoses take place when individuals are alone, or accompanied by others also using drugs. This means they are largely transitory and hidden events, with no opportunity for sampling. A key indicator, therefore, is those who do come into contact with first responders, who are administered the lifesaving opioid reversal drug naloxone, or who are admitted to hospital. Ambulance data represents an opportunity for rapidly identifying local spikes in overdoses and, for this purpose, we are establishing data feeds with ambulance trusts in England, on callouts where naloxone has been administered.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4117", "label" : {"_value" : "Biography information for Andrea Leadsom"} } , "answeringMemberConstituency" : {"_value" : "South Northamptonshire"} , "answeringMemberPrinted" : {"_value" : "Andrea Leadsom"} , "dateOfAnswer" : {"_value" : "2024-04-15", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-04-15T08:51:23.937Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-03-26", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Opioids: Overdoses"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether her Department is collating data from toxicology reports of non-fatal overdose incidents to assess the risk from synthetic opioids.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3930", "label" : {"_value" : "Biography information for Caroline Lucas"} } , "tablingMemberConstituency" : {"_value" : "Brighton, Pavilion"} , "tablingMemberPrinted" : [{"_value" : "Caroline Lucas"} ], "uin" : "20589"} , {"_about" : "http://data.parliament.uk/resources/1698924", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1698924/answer", "answerText" : {"_value" : "

Ministers have not met with Greater Manchester NHS Board about the statutory commissioning of National Institute for Health and Care Excellence (NICE) recommended medicines. Similarly I am informed that NHS England is not aware of any such discussions.<\/p>

The National Health Service in England is legally required to make funding available for treatments recommended in NICE technology appraisal and highly specialised technologies guidance, normally within three months of the publication of final guidance. This requirement is reflected in the NHS Constitution as a right to drugs and treatments that have been recommended by NICE for use in the NHS, if their doctor believes they are clinically appropriate.<\/p>

The NHS Standard Contract is mandated by NHS England for use by commissioners for all contracts for healthcare services other than primary care. The 2024/25 standard contract states that, where any service involves or may involve the prescribing of medicines, the provider must ensure that its formulary reflects all relevant positive NICE technology appraisals. NICE\u2019s guideline on developing and updating local formularies states that when a NICE technology appraisal recommends a medicine, it should be adopted into the local formulary automatically if clinically appropriate and relevant to the services provided by the organisation, and that this process should take place within three months.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"} } , "answeringMemberConstituency" : {"_value" : "Pendle"} , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"} , "dateOfAnswer" : {"_value" : "2024-04-15", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "20612"} , {"_value" : "20613"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-04-15T08:04:14.517Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-03-26", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "NHS Greater Manchester: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, when she last met with Greater Manchester NHS Board to discuss the statutory commissioning of NICE approved medicines.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4034", "label" : {"_value" : "Biography information for Yvonne Fovargue"} } , "tablingMemberConstituency" : {"_value" : "Makerfield"} , "tablingMemberPrinted" : [{"_value" : "Yvonne Fovargue"} ], "uin" : "20611"} , {"_about" : "http://data.parliament.uk/resources/1698925", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1698925/answer", "answerText" : {"_value" : "

Ministers have not met with Greater Manchester NHS Board about the statutory commissioning of National Institute for Health and Care Excellence (NICE) recommended medicines. Similarly I am informed that NHS England is not aware of any such discussions.<\/p>

The National Health Service in England is legally required to make funding available for treatments recommended in NICE technology appraisal and highly specialised technologies guidance, normally within three months of the publication of final guidance. This requirement is reflected in the NHS Constitution as a right to drugs and treatments that have been recommended by NICE for use in the NHS, if their doctor believes they are clinically appropriate.<\/p>

The NHS Standard Contract is mandated by NHS England for use by commissioners for all contracts for healthcare services other than primary care. The 2024/25 standard contract states that, where any service involves or may involve the prescribing of medicines, the provider must ensure that its formulary reflects all relevant positive NICE technology appraisals. NICE\u2019s guideline on developing and updating local formularies states that when a NICE technology appraisal recommends a medicine, it should be adopted into the local formulary automatically if clinically appropriate and relevant to the services provided by the organisation, and that this process should take place within three months.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"} } , "answeringMemberConstituency" : {"_value" : "Pendle"} , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"} , "dateOfAnswer" : {"_value" : "2024-04-15", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "20611"} , {"_value" : "20613"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-04-15T08:04:14.563Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-03-26", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "NHS Greater Manchester: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what discussions NHS England have had with Greater Manchester NHS on their statutory responsibilities to commission NICE approved medicines.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4034", "label" : {"_value" : "Biography information for Yvonne Fovargue"} } , "tablingMemberConstituency" : {"_value" : "Makerfield"} , "tablingMemberPrinted" : [{"_value" : "Yvonne Fovargue"} ], "uin" : "20612"} ], "itemsPerPage" : 10, "next" : "https://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&min-questionFirstAnswered.=2024-04-09T11%3A12%3A25.547Z&answeringDeptId=17&max-dateTabled=2024-03-27", "page" : 0, "startIndex" : 1, "totalResults" : 106, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]} }